HRP20020815A2 - Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations - Google Patents
Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations Download PDFInfo
- Publication number
- HRP20020815A2 HRP20020815A2 HRP20020815A HRP20020815A2 HR P20020815 A2 HRP20020815 A2 HR P20020815A2 HR P20020815 A HRP20020815 A HR P20020815A HR P20020815 A2 HRP20020815 A2 HR P20020815A2
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- hypertrophy
- cilobradine
- myocardial diseases
- pharmaceutical preparations
- Prior art date
Links
- 230000000059 bradycardiac effect Effects 0.000 title claims description 14
- 239000000126 substance Substances 0.000 title claims description 13
- 206010020880 Hypertrophy Diseases 0.000 title claims description 8
- 208000031229 Cardiomyopathies Diseases 0.000 title claims description 7
- 239000003814 drug Substances 0.000 title description 2
- OBUFMJDDZTXJPY-NRFANRHFSA-N 3-[[(3s)-1-[2-(3,4-dimethoxyphenyl)ethyl]piperidin-3-yl]methyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one Chemical compound C1=C(OC)C(OC)=CC=C1CCN1C[C@@H](CN2C(CC3=CC(OC)=C(OC)C=C3CC2)=O)CCC1 OBUFMJDDZTXJPY-NRFANRHFSA-N 0.000 claims description 22
- 229950010208 cilobradine Drugs 0.000 claims description 22
- 239000013543 active substance Substances 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000005541 ACE inhibitor Substances 0.000 claims description 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 239000003826 tablet Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 229920002261 Corn starch Polymers 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000008120 corn starch Substances 0.000 description 9
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229960001021 lactose monohydrate Drugs 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- OXTYVEUAQHPPMV-UHFFFAOYSA-N Alinidine Chemical compound ClC1=CC=CC(Cl)=C1N(CC=C)C1=NCCN1 OXTYVEUAQHPPMV-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 229950010767 alinidine Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- -1 carvedolol Chemical compound 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 229960003746 metildigoxin Drugs 0.000 description 2
- IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229960005187 telmisartan Drugs 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10018401A DE10018401A1 (de) | 2000-04-13 | 2000-04-13 | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| PCT/EP2001/004034 WO2001078699A2 (fr) | 2000-04-13 | 2001-04-07 | Utilisation d'agents bradycardiques dans le traitement de maladies myocardiaques accompagnees d'hypertrophie et nouvelles combinaisons pharmaceutiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20020815A2 true HRP20020815A2 (en) | 2004-12-31 |
Family
ID=7638652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20020815 HRP20020815A2 (en) | 2000-04-13 | 2002-10-11 | Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7208508B2 (fr) |
| EP (2) | EP1276476B1 (fr) |
| JP (1) | JP3905386B2 (fr) |
| KR (1) | KR20020089453A (fr) |
| CN (1) | CN1245963C (fr) |
| AT (1) | ATE330588T1 (fr) |
| AU (2) | AU7048401A (fr) |
| BG (1) | BG65816B1 (fr) |
| BR (1) | BR0109996A (fr) |
| CA (2) | CA2575059A1 (fr) |
| CY (1) | CY1105081T1 (fr) |
| CZ (1) | CZ300549B6 (fr) |
| DE (2) | DE10018401A1 (fr) |
| DK (1) | DK1276476T3 (fr) |
| EA (1) | EA006977B1 (fr) |
| EE (1) | EE05099B1 (fr) |
| ES (1) | ES2266216T3 (fr) |
| HR (1) | HRP20020815A2 (fr) |
| HU (1) | HU228387B1 (fr) |
| IL (2) | IL152103A0 (fr) |
| ME (1) | MEP45908A (fr) |
| MX (1) | MXPA02009935A (fr) |
| NO (1) | NO330311B1 (fr) |
| NZ (1) | NZ521934A (fr) |
| PL (1) | PL215235B1 (fr) |
| PT (1) | PT1276476E (fr) |
| RS (1) | RS51478B (fr) |
| SI (1) | SI1276476T1 (fr) |
| SK (1) | SK286075B6 (fr) |
| TR (1) | TR200202326T2 (fr) |
| UA (1) | UA78679C2 (fr) |
| WO (1) | WO2001078699A2 (fr) |
| ZA (1) | ZA200208162B (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10018401A1 (de) * | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| ATE257384T1 (de) * | 2002-07-25 | 2004-01-15 | Boehringer Ingelheim Pharma | Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen |
| US20040138306A1 (en) * | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| AU2004208615C1 (en) * | 2003-01-31 | 2010-05-13 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
| KR20130135994A (ko) * | 2005-06-27 | 2013-12-11 | 다이이찌 산쿄 가부시키가이샤 | 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를 함유한 약학 제제 |
| CA2617519A1 (fr) * | 2005-08-23 | 2007-03-01 | Astellas Pharma Inc. | Agent pour le traitement de la fibrillation auriculaire |
| EP1762179A1 (fr) | 2005-09-07 | 2007-03-14 | Boehringer Ingelheim Vetmedica Gmbh | Méthode pour l'amélioration de la qualité de diagnostic dans l'échocardiographie |
| FR2894825B1 (fr) * | 2005-12-21 | 2010-12-03 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent |
| TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
| EP1908469A1 (fr) * | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Antagonistes du récepteur de l'angiotensine II pour traiter des désordres sistémiques des chats |
| BRPI1013037A2 (pt) | 2009-05-20 | 2019-09-24 | Boehringer Ingelheim Ipharmaceuticals Inc | "solução farmacêutica oral de telmisartan" |
| FR2961105B1 (fr) * | 2010-06-15 | 2013-02-08 | Servier Lab | Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque |
| KR101296743B1 (ko) * | 2011-02-17 | 2013-08-20 | 한국과학기술연구원 | 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법 |
| CN103796638A (zh) | 2011-08-12 | 2014-05-14 | 勃林格殷格翰动物保健有限公司 | 遮味药物组合物 |
| EP2953612A1 (fr) | 2013-02-11 | 2015-12-16 | Boehringer Ingelheim Vetmedica GmbH | Kit d'éléments |
| US10905676B2 (en) | 2017-07-07 | 2021-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats |
| KR102398532B1 (ko) | 2020-07-20 | 2022-05-13 | 한림대학교 산학협력단 | 중증 지주막하출혈 진단용 조성물 |
| KR102331806B1 (ko) | 2020-07-20 | 2021-12-01 | 한림대학교 산학협력단 | 중증 지주막하출혈 진단용 바이오 마커 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759125A (fr) | 1969-11-19 | 1971-05-18 | Boehringer Sohn Ingelheim | Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer |
| DE3119874A1 (de) | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
| US5175157A (en) | 1985-11-27 | 1992-12-29 | Boehringer Ingelheim Gmbh | Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them |
| DE3541811A1 (de) | 1985-11-27 | 1987-06-04 | Thomae Gmbh Dr K | Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE3736866A1 (de) | 1987-10-30 | 1989-05-11 | Thomae Gmbh Dr K | Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz |
| DE3805635A1 (de) | 1988-02-24 | 1989-09-07 | Thomae Gmbh Dr K | Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica |
| US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
| RU2078536C1 (ru) * | 1993-09-02 | 1997-05-10 | Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско | Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией |
| CN1135757A (zh) | 1993-09-24 | 1996-11-13 | 普罗克特和甘保尔公司 | 新型含脱氧和氧被取代的糖的14-氨基类固醇 |
| US5595987A (en) * | 1994-07-22 | 1997-01-21 | The Trustees Of Columbia University In The City Of New York | Method of slowing ventricular arrhythmias using zatebradine |
| US6083991A (en) * | 1997-06-04 | 2000-07-04 | University Of Florida Research Foundation, Inc. | Anti-arrhythmic composition and methods of treatment |
| DE19741635A1 (de) | 1997-09-22 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| CZ299429B6 (cs) * | 1998-07-10 | 2008-07-23 | Novartis Ag | Lék obsahující kombinaci valsartanu a blokátoru kalciového kanálu |
| DE10018401A1 (de) | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| US20040138306A1 (en) | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| CA2435526A1 (fr) | 2002-07-25 | 2004-01-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Utilisation de derives d'amine cyclique ou de sels utilisables en pharmacie pour le traitement ou la prevention d'accidents cardiaques |
| EP1762179A1 (fr) * | 2005-09-07 | 2007-03-14 | Boehringer Ingelheim Vetmedica Gmbh | Méthode pour l'amélioration de la qualité de diagnostic dans l'échocardiographie |
-
2000
- 2000-04-13 DE DE10018401A patent/DE10018401A1/de not_active Withdrawn
-
2001
- 2001-04-07 PT PT01949281T patent/PT1276476E/pt unknown
- 2001-04-07 JP JP2001576000A patent/JP3905386B2/ja not_active Expired - Fee Related
- 2001-04-07 CN CNB018079598A patent/CN1245963C/zh not_active Expired - Fee Related
- 2001-04-07 MX MXPA02009935A patent/MXPA02009935A/es active IP Right Grant
- 2001-04-07 KR KR1020027013688A patent/KR20020089453A/ko not_active Application Discontinuation
- 2001-04-07 PL PL357827A patent/PL215235B1/pl unknown
- 2001-04-07 NZ NZ521934A patent/NZ521934A/en not_active IP Right Cessation
- 2001-04-07 CA CA002575059A patent/CA2575059A1/fr not_active Abandoned
- 2001-04-07 HU HU0300917A patent/HU228387B1/hu not_active IP Right Cessation
- 2001-04-07 ES ES01949281T patent/ES2266216T3/es not_active Expired - Lifetime
- 2001-04-07 ME MEP-459/08A patent/MEP45908A/xx unknown
- 2001-04-07 IL IL15210301A patent/IL152103A0/xx unknown
- 2001-04-07 BR BR0109996-5A patent/BR0109996A/pt active Pending
- 2001-04-07 AU AU7048401A patent/AU7048401A/xx active Pending
- 2001-04-07 EP EP01949281A patent/EP1276476B1/fr not_active Expired - Lifetime
- 2001-04-07 WO PCT/EP2001/004034 patent/WO2001078699A2/fr active IP Right Grant
- 2001-04-07 EP EP06111485A patent/EP1666042A3/fr not_active Withdrawn
- 2001-04-07 CZ CZ20023752A patent/CZ300549B6/cs not_active IP Right Cessation
- 2001-04-07 EE EEP200200590A patent/EE05099B1/xx not_active IP Right Cessation
- 2001-04-07 RS YUP-769/02A patent/RS51478B/sr unknown
- 2001-04-07 TR TR2002/02326T patent/TR200202326T2/xx unknown
- 2001-04-07 SK SK1458-2002A patent/SK286075B6/sk not_active IP Right Cessation
- 2001-04-07 EA EA200201053A patent/EA006977B1/ru not_active IP Right Cessation
- 2001-04-07 AT AT01949281T patent/ATE330588T1/de active
- 2001-04-07 AU AU2001270484A patent/AU2001270484B2/en not_active Ceased
- 2001-04-07 DK DK01949281T patent/DK1276476T3/da active
- 2001-04-07 SI SI200130616T patent/SI1276476T1/sl unknown
- 2001-04-07 US US10/257,481 patent/US7208508B2/en not_active Expired - Fee Related
- 2001-04-07 CA CA002404120A patent/CA2404120C/fr not_active Expired - Fee Related
- 2001-04-07 DE DE50110262T patent/DE50110262D1/de not_active Expired - Lifetime
- 2001-07-04 UA UA2002118949A patent/UA78679C2/uk unknown
-
2002
- 2002-09-13 BG BG107103A patent/BG65816B1/bg active Active
- 2002-10-03 IL IL152103A patent/IL152103A/en not_active IP Right Cessation
- 2002-10-10 ZA ZA200208162A patent/ZA200208162B/en unknown
- 2002-10-11 NO NO20024924A patent/NO330311B1/no not_active IP Right Cessation
- 2002-10-11 HR HRP20020815 patent/HRP20020815A2/hr not_active Application Discontinuation
-
2006
- 2006-07-07 CY CY20061100956T patent/CY1105081T1/el unknown
-
2007
- 2007-03-12 US US11/684,974 patent/US20070155679A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070155679A1 (en) | Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations | |
| RU2184563C2 (ru) | Твердая лекарственная форма, содержащая рамиприл в качестве ингибитора ангиотензинконвертирующего фермента, и соединение дигидропиридина | |
| CN102159284B (zh) | 3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和抗癫痫药的联合药物 | |
| EA014189B1 (ru) | Применение флибансерина для лечения расстройств полового влечения в предклимактерический период | |
| EA007274B1 (ru) | Применение флибансерина для лечения половых расстройств | |
| NZ506020A (en) | Use of pharmaceutical combinations containing tramadol and an antiemetic | |
| EP0471388B1 (fr) | Médicament pour le traitement de l'insuffisance cardiaque | |
| KR100325793B1 (ko) | 불안신경증치료제 | |
| RU2084225C1 (ru) | Гипотензивное средство | |
| CN101190890B (zh) | 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺 | |
| RU2174391C1 (ru) | Фармацевтическая композиция с антидепрессантной активностью | |
| RU2386439C2 (ru) | Фармацевтическая комбинация, включающая винпоцетин и бетагистин, для лечения недостаточности кровообращения мозга | |
| MXPA00007922A (en) | Pharmaceutical combinations containing tramadol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20110404 Year of fee payment: 11 |
|
| ODBI | Application refused |